— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share
— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected
— Net loss before recognition of the deemed dividends was $5.3 million
— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018
— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin
— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor
Most Popular
Key highlights from Pfizer’s (PFE) Q1 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its first quarter 2025 earnings results today. Revenues decreased 8% year-over-year to $13.7 billion. GAAP net income decreased 5% to $2.96 billion, or $0.52 per
PYPL Earnings: PayPal reports higher Q1 2025 revenue and profit
PayPal Holdings Inc. (NASDAQ: PYPL) on Tuesday reported a modest increase in revenue for the first quarter of 2025 when the payment service giant's adjusted earnings rose by double digits.
General Motors (GM) Q1 2025 revenue and adj. earnings beat estimates
Auto giant General Motors (NYSE: GM) on Tuesday announced financial results for the first quarter of 2025, reporting an increase in revenue and adjusted profit. The results also topped expectations.
